Skip to main content
Premium Trial:

Request an Annual Quote

Nanosphere to Effect a 20-to-1 Reverse Stock Split

NEW YORK (GenomeWeb) – Nanosphere today announced a 20-for-1 reverse stock split. 

The reverse split will take effect at 5:00 PM EDT on Wednesday and commence at the open of trading on April 9. Nanosphere's common stock will continue trading on the Nasdaq Capital Market under ticker symbol "NSPH," while a new CUSIP number, 63009F204, has been assigned to the common stock in connection to the reverse split. 

Nanosphere's shareholders approved the reverse split today, while its board determined the 20-to-1 ratio. As a result of the action, the number of Nanosphere's outstanding common shares will be reduced to about 5.9 million from 117.2 million, the firm said. 

The company had been notified in September 2014 by Nasdaq that it was in non-compliance with a listing requirement for a minimum closing bid price of $1. The following month, though, Nanosphere moved to the Nasdaq Capital Market from the Nasdaq Global Market, on which the company's shares had previously traded. 

The Nasdaq Capital Market has lower listing requirements than the Nasdaq Global Market.

In afternoon trading today, Nanosphere's shares rose about 9 percent to $.26.

The Scan

Cell Signaling Pathway Identified as Metastasis Suppressor

A new study in Nature homes in on the STING pathway as a suppressor of metastasis in a mouse model of lung cancer.

Using Bees to Gain Insights into Urban Microbiomes

As bees buzz around, they pick up debris that provides insight into the metagenome of their surroundings, researchers report in Environmental Microbiome.

Age, Genetic Risk Tied to Blood Lipid Changes in New Study

A study appearing in JAMA Network Open suggests strategies to address high lipid levels should focus on individuals with high genetic risk and at specific ages.

Study Examines Insights Gained by Adjunct Trio RNA Sequencing in Complex Pediatric Disease Cases

Researchers in AJHG explore the diagnostic utility of adding parent-child RNA-seq to genome sequencing in dozens of families with complex, undiagnosed genetic disease.